STAT Plus: Despite coronavirus disruption, major microbiome companies are cautiously optimistic about upcoming data
This was supposed to be the microbiome’s breakthrough year — and pandemic or not, it looks like it still might be.
Three companies — Finch Therapeutics, Seres Therapeutics, and Rebiotix — said earlier this year that they expected to announce results from pivotal clinical trials for recurrent C. difficile treatments sometime this summer.
Continue to STAT Plus to read the full story…
